Background and Purpose—The proinflammatory cytokine IL-1 (interleukin-1) has a
deleterious role in cerebral ischemia, which is attenuated by IL-1 receptor antagonist (IL …

Inflammation is established as a contributor to cerebrovascular disease. Risk factors for
stroke include many conditions associated with chronic or acute inflammation, and …

BACKGROUND: Interleukin (IL)-1 receptor antagonist (RA) is an anti-inflammatory protein
used to treat arthritis that has also been identified as a candidate stroke drug. METHODS …

INTRODUCTION: Infections are common following stroke and adversely affect outcome.
Cellular immune suppression associated with acute stroke may increase susceptibility to …

Stroke represents a global challenge and is a leading cause of permanent disability
worldwide. Despite much effort, translation of research findings to clinical benefit has not yet …

Background As critical mediators of local and systemic inflammatory responses, cytokines
are produced in the brain following ischaemic stroke. Some have been detected in the …

Elevated plasma levels of interleukin‐6 (IL‐6), a key regulator of the acute phase response
that includes increased fibrinogen synthesis, have recently been detected in patients with …

Objectives: The cytokine interleukin (IL)-1 mediates ischaemic brain damage in rodents. The
endogenous, highly selective, IL-1 receptor antagonist (IL-1ra) protects against ischaemic …

Summary/Abstract Interleukin-1 receptor antagonist (IL-1 RA) is an anti-inflammatory protein
used clinically to treat rheumatoid arthritis and is considered a promising candidate therapy …

Background—Mechanisms involved in stroke progression are incompletely understood.
Ischemic brain injury is characterized by acute local inflammatory response mediated by …